Why Trillium (Nasdaq: TRIL) Stock Is Today's Top Biotech Buy
July 01, 2015 at 15:07 PM EDT
Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has climbed 143% in 2015, and it's still one of the top biotech stocks to buy now. You see, Trillium is at the forefront of a revolutionary treatment that could hold the key to curing various types of cancer. Here's how the treatment works, and how it could make TRIL stock the next great biotech blockbuster... Tags: Best Biotech Stocks , biotech stock , biotech stocks , biotech stocks to buy , Nasdaq: TRIL , top biotech stocks , TRIL , TRIL stock , TRILLIUM , Trillium stock To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Why Trillium (Nasdaq: TRIL) Stock Is Today's Top Biotech Buy appeared first on Money Morning - We Make Investing Profitable .